Stories published to our news archive may contain outdated information or links that are no longer active. Please note we do not update stories once they have been moved to the archive. Access and use the information in the stories at your own discretion. If you have questions or would like updated information on a story covered here, please contact Medtronic Public Relations at riley.mclaughlin@medtronic.com.
New app collects event data linked with Fitbit activity trackers empowering patients and physicians to get more out of continuous glucose monitoring.
When leaders in diabetes management partner with the leaders in wearable fitness devices - something meaningful is bound to happen.
In December, Fitbit, a leader in the connected health and fitness market announced it was teaming up with Medtronic to provide a unique activity tracking platform for patients living with diabetes, and their doctors.
The two companies are already hard at work.
Together, they have released “iPro2 myLog,” an innovative new app allowing patients with type 2 diabetes to easily capture activity information which, when used in conjunction with their personalized sensor glucose profile, provides valuable context to the variability in glucose levels.
Medtronic and Fitbit plan to offer patients even more solutions in the future.
“This partnership underscores our commitment to transforming diabetes care,” said Laura Stoltenberg, vice president and general manager of Non-Intensive Diabetes Therapies at Medtronic.
For those living with diabetes, balancing glucose levels is part of their daily experience and exercise can often cause those levels to go too high or too low. But, by combining data captured by Fitbit’s wearable technology along with sensor and glucose data from Medtronic’s medical devices, patients are provided with a better understanding of how to manage their diabetes and how exercise and activity play a role.
"We believe the integration of wearable technology with professional diagnostic tools can provide a more accurate and actionable view of a patient's physical activity," said Adam Pellegrini, vice president of Digital Health for Fitbit. "By partnering with Medtronic, we are able to bring the power of Fitbit's automatic activity tracking together with continuous glucose monitoring, allowing patients and providers to have a more informed conversation."
Providing solutions for diabetes patients that “offer greater freedom and better health” is a top priority for Medtronic, says Stoltenberg.
“Many patients are manually tracking and recording their physical activity, requiring them to recall and communicate that information to their physician from memory,” she says. “iPro2 myLog will simplify the sharing of important information.”
iPro2 myLog is currently available for Android and iOS smartphones for patients undergoing evaluation with Medtronic's iPro2 professional continuous glucose monitoring system.